Adverse Event Monitoring in Digital and Social Pharma Media
How pharma handles adverse events in digital and social media: what counts, monitoring scope, routing to safety teams, and partner duties.
The short answer
When a pharma company or its agencies encounter a possible adverse event in digital or social media they control or sponsor, such as a comment describing a side effect, it must be captured and routed to pharmacovigilance for assessment. Brands define which channels they monitor, train agencies and vendors to recognize reportable information, set timelines for forwarding, and moderate comments in a way that does not suppress safety information.
Digital campaigns invite responses. Some of those responses describe side effects. A pharma company has safety reporting obligations, and information that reaches the company through its digital channels can trigger them. Media and social teams are part of that process whether they think of themselves that way or not.
What counts
Pharmacovigilance teams typically look for four elements in a report:
- An identifiable patient.
- An identifiable reporter.
- A suspect product.
- An adverse event.
Even incomplete information may need to be forwarded for assessment. Media teams should not decide whether something is reportable; they should forward anything that might be.
Which channels are in scope
| Channel | Typical approach |
|---|---|
| Brand-owned social pages | Monitored; comments captured |
| Paid social ad comments | Monitored for the campaign duration |
| Brand websites with forms or chat | Captured through the site process |
| Sponsored influencer content | Contract requires monitoring and forwarding |
| Market research | Researchers trained to capture AEs |
| Third-party open social | Policy-dependent; often not systematically monitored |
Follow your company's pharmacovigilance procedures. They define scope and timelines.
Setting up a campaign
- Before launch: confirm which channels allow comments, who monitors, and how often.
- Training: agency and vendor staff complete AE recognition training.
- Routing: a clear path to pharmacovigilance with required timelines.
- Moderation rules: capture first, then moderate according to policy.
- Records: keep logs of captured items and forwarding times.
Comment strategy
Brands choose whether to allow comments on paid social:
- Comments on: more engagement, more monitoring work.
- Comments limited or off: less monitoring, but some platforms do not allow turning comments off in all placements.
Either way, plan for monitoring. See DTC pharma social media advertising.
Partner contracts
Agencies, social vendors, research firms, and influencers should have contract terms covering:
- AE recognition training.
- Forwarding timelines.
- Monitoring scope and frequency.
- Record keeping.
Common mistakes
- Launching social campaigns without monitoring plans.
- Deleting comments before capturing them.
- Untrained agency staff deciding what is reportable.
- Influencer contracts with no AE terms.
Practical takeaway
Before your next social or influencer campaign, run a tabletop test: post a mock comment describing a side effect and time how long it takes to reach pharmacovigilance through your actual process. The result shows whether the process works before a real report tests it.
Frequently asked questions
What makes a comment a reportable adverse event?
Companies commonly use four elements: an identifiable patient, an identifiable reporter, a suspect product, and an adverse event. Pharmacovigilance teams make the formal assessment.
Do brands need to monitor all of social media?
Companies generally focus on channels they own, control, or sponsor. Policies differ, so follow your company's pharmacovigilance procedures.
Can brands delete comments mentioning side effects?
Moderation rules should make sure safety information is captured and forwarded before any action. Deleting without capture creates risk.
Sources
- FDA, MedWatch Safety Information and Adverse Event Reporting Program
- Federal Register, Draft Guidance on Internet/Social Media Platforms With Character Space Limitations (2014)
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.